{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:08:48Z","timestamp":1789459728774,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"DOI":"10.1038\/s41401-026-01931-5","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:38:42Z","timestamp":1789457922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lvguidingan inhibits Nav1.2 and epilepsy-associated SCN2A gain-of-function variants"],"prefix":"10.1038","author":[{"given":"Long","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-yong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-hong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-bing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"1931_CR1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1124\/pr.120.019539","volume":"72","author":"W Loscher","year":"2020","unstructured":"Loscher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72:606\u201338.","journal-title":"Pharmacol Rev"},{"key":"1931_CR2","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ncl.2016.06.015","volume":"34","author":"A Singh","year":"2016","unstructured":"Singh A, Trevick S. The epidemiology of global epilepsy. Neurol Clin. 2016;34:837\u201347.","journal-title":"Neurol Clin."},{"key":"1931_CR3","doi-asserted-by":"publisher","first-page":"e92961","DOI":"10.1371\/journal.pone.0092961","volume":"9","author":"XW Gong","year":"2014","unstructured":"Gong XW, Li JB, Lu QC, Liang PJ, Zhang PM. Effective connectivity of hippocampal neural network and its alteration in Mg2+-free epilepsy model. PLoS One. 2014;9:e92961.","journal-title":"PLoS One"},{"key":"1931_CR4","doi-asserted-by":"crossref","unstructured":"Zhang S, Zhu Y, Cheng J, Tao J. Ion channels in epilepsy: blasting fuse for neuronal hyperexcitability. In: Al-Zwaini IJ, Albadri BA-H, editors. Epilepsy - advances in diagnosis and therapy. London: IntechOpen; 2019.","DOI":"10.5772\/intechopen.83698"},{"key":"1931_CR5","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.3390\/biomedicines13092078","volume":"13","author":"A Gyamfi","year":"2025","unstructured":"Gyamfi A, Manikandan P, Cisneros WA, Cummins TR, Marrs JA. Voltage-gated sodium channel dysfunction in epilepsy: zebrafish models for therapeutics. Biomedicines. 2025;13:2078.","journal-title":"Biomedicines"},{"key":"1931_CR6","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.4103\/NRR.NRR-D-25-00260","volume":"21","author":"N Li","year":"2026","unstructured":"Li N, Yan L, Peng A, Fu X, Qin H, Yao K. Voltage-gated sodium channels in the nervous system: molecular physiology to therapeutic interventions. Neural Regen Res. 2026;21:2085\u2013100.","journal-title":"Neural Regen Res"},{"key":"1931_CR7","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3389\/fphar.2020.01276","volume":"11","author":"LFS Menezes","year":"2020","unstructured":"Menezes LFS, Sabia Junior EF, Tibery DV, Carneiro LDA, Schwartz EF. Epilepsy-related voltage-gated sodium channelopathies: a review. Front Pharmacol. 2020;11:1276.","journal-title":"Front Pharmacol"},{"key":"1931_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.908867","volume":"13","author":"D Jiang","year":"2022","unstructured":"Jiang D, Zhang J, Xia Z. Structural advances in voltage-gated sodium channels. Front Pharmacol. 2022;13:908867.","journal-title":"Front Pharmacol"},{"key":"1931_CR9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1080\/19336950.2017.1380758","volume":"11","author":"J Wang","year":"2017","unstructured":"Wang J, Ou SW, Wang YJ. Distribution and function of voltage-gated sodium channels in the nervous system. Channels. 2017;11:534\u201354.","journal-title":"Channels"},{"key":"1931_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4161\/chan.24380","volume":"7","author":"M Abdelsayed","year":"2013","unstructured":"Abdelsayed M, Sokolov S. Voltage-gated sodium channels: pharmaceutical targets via anticonvulsants to treat epileptic syndromes. Channels. 2013;7:146\u201352.","journal-title":"Channels"},{"key":"1931_CR11","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/brain\/awx054","volume":"140","author":"M Wolff","year":"2017","unstructured":"Wolff M, Johannesen KM, Hedrich UBS, Masnada S, Rubboli G, Gardella E, et al. Genetic and phenotypic heterogeneity suggests therapeutic implications in SCN2A-related disorders. Brain. 2017;140:1316\u201336.","journal-title":"Brain"},{"key":"1931_CR12","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.202313375","volume":"155","author":"CH Thompson","year":"2023","unstructured":"Thompson CH, Potet F, Abramova TV, DeKeyser JM, Ghabra NF, Vanoye CG, et al. Epilepsy-associated SCN2A (NaV1.2) variants exhibit diverse and complex functional properties. J Gen Physiol. 2023;155:e202313375.","journal-title":"J Gen Physiol"},{"key":"1931_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105230","volume":"115","author":"R Pal","year":"2021","unstructured":"Pal R, Kumar B, Akhtar MJ, Chawla PA. Voltage-gated sodium channel inhibitors as anticonvulsant drugs: a systematic review on recent developments and structure-activity relationship studies. Bioorg Chem. 2021;115:105230.","journal-title":"Bioorg Chem"},{"key":"1931_CR14","doi-asserted-by":"crossref","unstructured":"Yamakawa K, Meisler MH, Isom LL. Sodium channelopathies in human and animal models of epilepsy and neurodevelopmental disorders. In: Noebels JL, Avoli M, Rogawski MA, Vezzani A, Delgado-Escueta AV, editors. Jasper\u2019s Basic Mechanisms of the Epilepsies. 5th ed. New York: Oxford University Press; 2024. p 881\u2013920.","DOI":"10.1093\/med\/9780197549469.003.0044"},{"key":"1931_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41583-020-00418-4","volume":"22","author":"MH Meisler","year":"2021","unstructured":"Meisler MH, Hill SF, Yu W. Sodium channelopathies in neurodevelopmental disorders. Nat Rev Neurosci. 2021;22:152\u201366.","journal-title":"Nat Rev Neurosci"},{"key":"1931_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/epi.13634","volume":"58","author":"M Bialer","year":"2017","unstructured":"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia. 2017;58:181\u2013221.","journal-title":"Epilepsia"},{"key":"1931_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2026.118550","volume":"134","author":"Y Zhou","year":"2026","unstructured":"Zhou Y, Wang W, Lv C, Wu J, Lv S, He L, et al. Novel 7-substituted-1,2,4-Triazolopyrimidines targeting Nav1.2 channels as low-neurotoxicity antiepileptic agents. Bioorg Med Chem. 2026;134:118550.","journal-title":"Bioorg Med Chem"},{"key":"1931_CR18","doi-asserted-by":"publisher","first-page":"7083","DOI":"10.1021\/acs.jcim.3c00645","volume":"63","author":"MA Llanos","year":"2023","unstructured":"Llanos MA, Enrique N, Esteban-Lopez V, Scioli-Montoto S, Sanchez-Benito D, Ruiz ME, et al. A combined ligand- and structure-based virtual screening to identify novel NaV1.2 blockers: In vitro patch clamp validation and in vivo anticonvulsant activity. J Chem Inf Model. 2023;63:7083\u201396.","journal-title":"J Chem Inf Model"},{"key":"1931_CR19","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1021\/acschemneuro.3c00757","volume":"15","author":"SJ Goodchild","year":"2024","unstructured":"Goodchild SJ, Shuart NG, Williams AD, Ye W, Parrish RR, Soriano M, et al. Molecular pharmacology of selective NaV1.6 and dual NaV1.6\/NaV1.2 channel inhibitors that suppress excitatory neuronal activity ex vivo. ACS Chem Neurosci. 2024;15:1169\u201384.","journal-title":"ACS Chem Neurosci"},{"key":"1931_CR20","doi-asserted-by":"publisher","first-page":"12912","DOI":"10.1021\/acs.jmedchem.4c00861","volume":"67","author":"G He","year":"2024","unstructured":"He G, Zheng Y, Chang S, Wang L, Yang X, Hao H, et al. Discovery of novel pyrimidine-based derivatives as Nav1.2 inhibitors with efficacy in mouse models of epilepsy. J Med Chem. 2024;67:12912\u201331.","journal-title":"J Med Chem"},{"key":"1931_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117664","volume":"292","author":"B Lou","year":"2025","unstructured":"Lou B, Liang W, Jiang N, Guo Y, Zhang T, Guo C, et al. Discovery of novel 4-azaindole derivatives as selective Nav1.2 inhibitors with potent antiepileptic activity and low neurotoxicity. Eur J Med Chem. 2025;292:117664.","journal-title":"Eur J Med Chem"},{"key":"1931_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1528-1157.1983.tb04877.x","volume":"24","author":"YQ Pei","year":"1983","unstructured":"Pei YQ. A review of the pharmacology and clinical use of piperine and its derivatives. Epilepsia. 1983;24:177\u201382.","journal-title":"Epilepsia"},{"key":"1931_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1517\/13543776.2016.1118057","volume":"26","author":"D Chavarria","year":"2016","unstructured":"Chavarria D, Silva T, Magalhaes e Silva D, Remiao F, Borges F. Lessons from black pepper: piperine and derivatives thereof. Expert Opin Ther Pat. 2016;26:245\u201364.","journal-title":"Expert Opin Ther Pat"},{"key":"1931_CR24","first-page":"736","volume":"17","author":"LG Cao","year":"1982","unstructured":"Cao LG, Pei YQ. The pharmacological actions of 3,4-dichlorophenyl propenoyl isobutylamide on the central nervous system. Yao Xue Xue Bao. 1982;17:736\u201343.","journal-title":"Yao Xue Xue Bao"},{"key":"1931_CR25","first-page":"889","volume":"17","author":"LG Cao","year":"1982","unstructured":"Cao LG, Pei YQ. Analysis of the mechanism of anticonvulsant action of 3, 4-dichlorophenyl propenyl isobutylamide (7903). Yao Xue Xue Bao. 1982;17:889\u201393.","journal-title":"Yao Xue Xue Bao"},{"key":"1931_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41401-019-0327-4","volume":"41","author":"ZQ Xie","year":"2020","unstructured":"Xie ZQ, Tian XT, Zheng YM, Zhan L, Chen XQ, Xin XM, et al. Antiepileptic geissoschizine methyl ether is an inhibitor of multiple neuronal channels. Acta Pharmacol Sin. 2020;41:629\u201337.","journal-title":"Acta Pharmacol Sin"},{"key":"1931_CR27","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1126\/science.aaw2999","volume":"363","author":"X Pan","year":"2019","unstructured":"Pan X, Li Z, Huang X, Huang G, Gao S, Shen H, et al. Molecular basis for pore blockade of human Na+ channel Nav1.2 by the mu-conotoxin KIIIA. Science. 2019;363:1309\u201313.","journal-title":"Science"},{"key":"1931_CR28","doi-asserted-by":"publisher","first-page":"2.9.1","DOI":"10.1002\/cpps.20","volume":"86","author":"B Webb","year":"2016","unstructured":"Webb B, Sali A. Comparative protein structure modeling using modelLER. Curr Protoc Protein Sci. 2016;86:2.9.1\u20132.9.37.","journal-title":"Curr Protoc Protein Sci"},{"key":"1931_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng EC, Goddard TD, Pettersen EF, Couch GS, Pearson ZJ, Morris JH, et al. UCSF ChimeraX: Tools for structure building and analysis. Protein Sci. 2023;32:e4792.","journal-title":"Protein Sci"},{"key":"1931_CR30","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1002\/jcc.23702","volume":"35","author":"EL Wu","year":"2014","unstructured":"Wu EL, Cheng X, Jo S, Rui H, Song KC, Davila-Contreras EM, et al. CHARMM-GUI Membrane Builder toward realistic biological membrane simulations. J Comput Chem. 2014;35:1997\u20132004.","journal-title":"J Comput Chem"},{"key":"1931_CR31","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1021\/ct400341p","volume":"9","author":"DR Roe","year":"2013","unstructured":"Roe DR, Cheatham TE. 3rd. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput. 2013;9:3084\u201395.","journal-title":"J Chem Theory Comput"},{"key":"1931_CR32","doi-asserted-by":"publisher","first-page":"962","DOI":"10.2174\/156802612800229206","volume":"12","author":"V Zuliani","year":"2012","unstructured":"Zuliani V, Fantini M, Rivara M. Sodium channel blockers as therapeutic target for treating epilepsy: recent updates. Curr Top Med Chem. 2012;12:962\u201370.","journal-title":"Curr Top Med Chem"},{"key":"1931_CR33","doi-asserted-by":"publisher","first-page":"E5516","DOI":"10.1073\/pnas.1800077115","volume":"115","author":"G Berecki","year":"2018","unstructured":"Berecki G, Howell KB, Deerasooriya YH, Cilio MR, Oliva MK, Kaplan D, et al. Dynamic action potential clamp predicts functional separation in mild familial and severe de novo forms of SCN2A epilepsy. Proc Natl Acad Sci USA. 2018;115:E5516\u2013E25.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1931_CR34","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.nbd.2014.03.007","volume":"67","author":"MK Oliva","year":"2014","unstructured":"Oliva MK, McGarr TC, Beyer BJ, Gazina E, Kaplan DI, Cordeiro L, et al. Physiological and genetic analysis of multiple sodium channel variants in a model of genetic absence epilepsy. Neurobiol Dis. 2014;67:180\u201390.","journal-title":"Neurobiol Dis"},{"key":"1931_CR35","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1111\/epi.14935","volume":"60","author":"M Wolff","year":"2019","unstructured":"Wolff M, Brunklaus A, Zuberi SM. Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond. Epilepsia. 2019;60:S59\u2013S67.","journal-title":"Epilepsia"},{"key":"1931_CR36","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40263-017-0441-0","volume":"31","author":"MJ Brodie","year":"2017","unstructured":"Brodie MJ. Sodium channel blockers in the treatment of epilepsy. CNS Drugs. 2017;31:527\u201334.","journal-title":"CNS Drugs"},{"key":"1931_CR37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/BF00310517","volume":"88","author":"N Ludvig","year":"1986","unstructured":"Ludvig N, Gyorgy L, Vizi ES. Evidence that serotonin receptors are involved in the anticonvulsant effect of yohimbine in mice. Psychopharmacology. 1986;88:82\u20135.","journal-title":"Psychopharmacology"},{"key":"1931_CR38","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/aps.2014.30","volume":"35","author":"JH Lee","year":"2014","unstructured":"Lee JH, Liu J, Shin M, Hong M, Nah SY, Bae H. Metergoline inhibits the neuronal Nav1.2 voltage-dependent Na+ channels expressed in Xenopus oocytes. Acta Pharmacol Sin. 2014;35:862\u20138.","journal-title":"Acta Pharmacol Sin"},{"key":"1931_CR39","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/bph.12150","volume":"169","author":"CH Peters","year":"2013","unstructured":"Peters CH, Sokolov S, Rajamani S, Ruben PC. Effects of the antianginal drug, ranolazine, on the brain sodium channel NaV1.2 and its modulation by extracellular protons. Br J Pharmacol. 2013;169:704\u201316.","journal-title":"Br J Pharmacol"},{"key":"1931_CR40","doi-asserted-by":"publisher","first-page":"9019","DOI":"10.1021\/jm400894u","volume":"56","author":"DF McComsey","year":"2013","unstructured":"McComsey DF, Smith-Swintosky VL, Parker MH, Brenneman DE, Malatynska E, White HS, et al. Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112). J Med Chem. 2013;56:9019\u201330.","journal-title":"J Med Chem"},{"key":"1931_CR41","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fphar.2011.00068","volume":"2","author":"HA Fozzard","year":"2011","unstructured":"Fozzard HA, Sheets MF, Hanck DA. The sodium channel as a target for local anesthetic drugs. Front Pharmacol. 2011;2:68.","journal-title":"Front Pharmacol"},{"key":"1931_CR42","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1528-1167.2007.01413.x","volume":"49","author":"KB Kile","year":"2008","unstructured":"Kile KB, Tian N, Durand DM. Scn2a sodium channel mutation results in hyperexcitability in the hippocampus in vitro. Epilepsia. 2008;49:488\u201399.","journal-title":"Epilepsia"},{"key":"1931_CR43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.biopsych.2017.01.009","volume":"82","author":"R Ben-Shalom","year":"2017","unstructured":"Ben-Shalom R, Keeshen CM, Berrios KN, An JY, Sanders SJ, Bender KJ. Opposing effects on Nav1.2 function underlie differences between SCN2A variants observed in individuals with autism spectrum disorder or infantile seizures. Biol Psychiatry. 2017;82:224\u201332.","journal-title":"Biol Psychiatry"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01931-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01931-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01931-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:38:49Z","timestamp":1789457929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01931-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":43,"alternative-id":["1931"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01931-5","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}